PL2493930T3 - Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania - Google Patents

Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania

Info

Publication number
PL2493930T3
PL2493930T3 PL10826929T PL10826929T PL2493930T3 PL 2493930 T3 PL2493930 T3 PL 2493930T3 PL 10826929 T PL10826929 T PL 10826929T PL 10826929 T PL10826929 T PL 10826929T PL 2493930 T3 PL2493930 T3 PL 2493930T3
Authority
PL
Poland
Prior art keywords
fraktalkine
antibodies
improved anti
anti human
human
Prior art date
Application number
PL10826929T
Other languages
English (en)
Inventor
Miyuki Nishimura
Yoshimasa Sakamoto
Tetsu Kawano
Toshio Imai
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493930(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of PL2493930T3 publication Critical patent/PL2493930T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10826929T 2009-10-30 2010-10-28 Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania PL2493930T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders
EP10826929.1A EP2493930B1 (en) 2009-10-30 2010-10-28 Improved anti human Fraktalkine antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PL2493930T3 true PL2493930T3 (pl) 2019-03-29

Family

ID=43922220

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10826929T PL2493930T3 (pl) 2009-10-30 2010-10-28 Udoskonalone przeciwciała przeciwko ludzkiej fraktalkinie i ich zastosowania

Country Status (33)

Country Link
US (1) US8932592B2 (pl)
EP (1) EP2493930B1 (pl)
JP (2) JP5631991B2 (pl)
KR (2) KR101627605B1 (pl)
CN (1) CN102597003B (pl)
AR (2) AR078796A1 (pl)
AU (1) AU2010312408B2 (pl)
BR (1) BR112012010266A2 (pl)
CA (1) CA2778895C (pl)
CL (2) CL2012001143A1 (pl)
CY (1) CY1121167T1 (pl)
DK (1) DK2493930T3 (pl)
ES (1) ES2698389T3 (pl)
HR (1) HRP20181973T1 (pl)
HU (1) HUE041952T2 (pl)
IL (1) IL219470A (pl)
JO (1) JO3437B1 (pl)
LT (1) LT2493930T (pl)
MX (1) MX2012005052A (pl)
MY (1) MY158481A (pl)
NZ (1) NZ599779A (pl)
PE (1) PE20121645A1 (pl)
PH (1) PH12012500828A1 (pl)
PL (1) PL2493930T3 (pl)
PT (1) PT2493930T (pl)
RS (1) RS58142B1 (pl)
RU (1) RU2569109C2 (pl)
SI (1) SI2493930T1 (pl)
SM (1) SMT201800637T1 (pl)
TW (1) TWI414308B (pl)
UA (1) UA105073C2 (pl)
WO (1) WO2011052799A1 (pl)
ZA (1) ZA201203002B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
KR102569813B1 (ko) 2014-11-21 2023-08-24 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
CN113929770A (zh) 2014-11-21 2022-01-14 百时美施贵宝公司 包含修饰的重链恒定区的抗体
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
JP7550142B2 (ja) * 2019-04-23 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチ治療のためのバイオマーカー
EP4073110A1 (en) * 2019-12-09 2022-10-19 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2022092183A1 (ja) 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
JPH11503030A (ja) 1996-01-24 1999-03-23 シェーリング コーポレイション 哺乳動物ｃｘ３ｃケモカイン遺伝子
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
EP0966484A4 (en) 1996-05-07 2002-04-17 Millennium Pharm Inc NEUROTACTIN AND APPLICATIONS THEREOF
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
CA2341361A1 (en) 1998-08-31 2000-03-09 Oregon Health Sciences University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
ES2330731T3 (es) 2001-08-30 2009-12-15 Chemocentryx, Inc. Compuestos biciclicos como inhibidores de la union de quimioquina a us28.
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
WO2005032589A1 (ja) 2003-10-02 2005-04-14 Japan Science And Technology Agency Ｇｖｈｄの予防及び治療
KR20060120014A (ko) 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
JP4958555B2 (ja) * 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
PT2094728E (pt) 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団

Also Published As

Publication number Publication date
RU2012122203A (ru) 2013-12-10
US20120213799A1 (en) 2012-08-23
CN102597003A (zh) 2012-07-18
EP2493930A4 (en) 2013-12-04
DK2493930T3 (en) 2018-12-17
WO2011052799A1 (en) 2011-05-05
PH12012500828A1 (en) 2013-01-07
LT2493930T (lt) 2019-01-10
JP2013509158A (ja) 2013-03-14
BR112012010266A2 (pt) 2016-12-06
JO3437B1 (ar) 2019-10-20
CL2012001143A1 (es) 2012-10-05
IL219470A0 (en) 2012-06-28
AR078796A1 (es) 2011-12-07
SI2493930T1 (sl) 2018-12-31
KR20120104560A (ko) 2012-09-21
IL219470A (en) 2017-10-31
TW201127401A (en) 2011-08-16
RU2569109C2 (ru) 2015-11-20
CY1121167T1 (el) 2020-05-29
ES2698389T3 (es) 2019-02-04
HUE041952T2 (hu) 2019-06-28
JP5631991B2 (ja) 2014-11-26
CN102597003B (zh) 2016-03-23
AR109533A2 (es) 2018-12-19
PT2493930T (pt) 2018-11-29
HRP20181973T1 (hr) 2019-01-25
TWI414308B (zh) 2013-11-11
KR101627605B1 (ko) 2016-06-07
KR20160066055A (ko) 2016-06-09
AU2010312408A1 (en) 2012-06-21
CL2015000114A1 (es) 2015-04-10
ZA201203002B (en) 2013-06-26
NZ599779A (en) 2014-03-28
MY158481A (en) 2016-10-14
US8932592B2 (en) 2015-01-13
SMT201800637T1 (it) 2019-01-11
EP2493930A1 (en) 2012-09-05
RS58142B1 (sr) 2019-02-28
AU2010312408B2 (en) 2015-07-09
JP2015027304A (ja) 2015-02-12
EP2493930B1 (en) 2018-09-19
CA2778895C (en) 2018-08-07
KR102099596B1 (ko) 2020-04-10
CA2778895A1 (en) 2011-05-05
PE20121645A1 (es) 2012-12-06
MX2012005052A (es) 2012-05-29
UA105073C2 (uk) 2014-04-10

Similar Documents

Publication Publication Date Title
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201107486B (en) Anti-tnf-x antibodies and their uses
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
GB0922434D0 (en) antibodies and fragments thereof
ZA201108310B (en) Blocking anti-dkk-1 antibodies and their uses
SMT201800637T1 (it) Anticorpi anti-fractalchina umana migliorati e utilizzi degli stessi
SG10201609416XA (en) NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
LT2946791T (lt) Anti-cd277 antikūnai ir jų panaudojimas
ZA201107555B (en) Anti-17f antibodies and methods of use thereof
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
GB0807018D0 (en) Antibodies and treatment
IL214355A0 (en) Antibodies against human tweak and uses thereof
GB0903151D0 (en) Antibody uses and methods
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
IL219136A0 (en) Anti-hepsin antibodies and methods using same
IL216440A0 (en) Antibodies against human ccn1 and uses thereof
GB0906115D0 (en) Antibody and uses thereof
GB0911407D0 (en) Antibody and diagnostic use